Question 1

Does JPMorgan Chase own CVKD stock?

Accepted Answer

No. JPMorgan Chase exited its CVKD (Cadrenal Therapeutics) position in Q2 2026. Its Q1 2026 13F listed 7,500 shares worth $31,875.

Question 2

How many shares of CVKD does JPMorgan Chase own?

Accepted Answer

None since Q2 2026, when JPMorgan Chase exited the position. Its Q1 2026 13F listed 7,500 shares worth $31,875.

Question 3

What is JPMorgan Chase's CVKD position worth?

Accepted Answer

JPMorgan Chase's CVKD position was worth $31,875 in its Q1 2026 13F, before the exit in Q2 2026.

Question 4

Is JPMorgan Chase buying or selling CVKD?

Accepted Answer

In Q2 2026, JPMorgan Chase exited its entire CVKD position.

Question 5

When did JPMorgan Chase first buy CVKD?

Accepted Answer

JPMorgan Chase first reported CVKD in its Q1 2025 13F and listed it in 4 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Exited	0	-100.0%	$0	0.0%	$3.34	0
2026-Q1	Unchanged	7,500	0.0%	$31,875	0.0%	$5.12	0
2025-Q4	Unchanged	7,500	0.0%	$50,850	0.0%	$6.78	0
2025-Q3	New	7,500	-	$103,313	0.0%	$13.83	33
2025-Q2	Exited	0	-100.0%	$0	0.0%	$12.05	0
2025-Q1	New	100	-	$1,763	0.0%	$17.63	17

CVKD6 quarters

CVKD
6 quarters